Skip to content

Drinking water and weight loss in overweight adolescents

Drinking water to dilute urine osmolality is associated with greater weight loss than drinking water following thirst in overweight pre-adolescents eating lower glycemic foods: A completer?s analysis of a controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN36031640
Enrollment
30
Registered
2013-01-18
Start date
2010-01-09
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight / Weight loss Nutritional, Metabolic, Endocrine Obesity

Interventions

Drinking water treatments All participants were instructed to drink water to minimize blood carbohydrate and insulin levels and maximize fat oxidation. They were told that drinking water was expected

Sponsors

Children's Hospital Oakland Research Institute (USA)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. All participants were screened for a body mass index (BMI) above the 85th percentile for age and sex 2. Motivation to lose weight 3. Daily intake of caloric beverages, including juice, soda, milks, and/or sports drinks, less than 2L per day drinking water 4. Willingness to adopt food and beverage changes 5. Boys and girls, at any stage of puberty 6. Who spoke English or Spanish

Exclusion criteria

Exclusion criteria: 1. Any health condition that could make study participation harmful 2. Acute illness 3. A fluid balance disorder 4. Any chronic condition or medication that stimulates vasopressin release, or any condition for which venipuncture is counter indicated. 5. Potential participants were also excluded if they had any condition or medication known to promote weight gain. 6. Specific exclusion criteria included: 6.1. Renal disease (previous diagnosis, +3 proteinuria dipstick test, frequent urination) 6.2. Congestive heart failure 6.3. Adrenal insufficiency 6.4. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 6.5. Chronic pain 6.6. Psychogenic polydipsia 6.7. Bleeding disorders 6.8. Hemophila 6.9. Recent cancer chemotherapy 6.10. Syndromic conditions (e.g. Prader-Willi, Bardet-Biedl) 6.11. Weight loss pharmacotherapy 6.12. Anti-depressent, anti-psychotic or lipid-lowering medications, adrenergic or cholinergic drugs, clofibrate, chlorpropamide, carbamazepine, phenothiazines, vincristine, cyclophosphamide, morphine barbiturates, opiates, and glucocorticoid therapy in excess of physiologic dosing (i.e. > 15 mg/m2/d). 7. Persons who had lost weight in the previous 2 months were excluded 8. Persons who expressed aversion to drinking water or the prescribed study foods, or who had plans to move to a new address during the study period were also excluded from the study

Design outcomes

Primary

MeasureTime frame
Body weight was measured in duplicate, using a calibrated clinical scale, at baseline, and then weekly for 8 consecutive weeks.

Secondary

MeasureTime frame
Saliva insulin - Unstimulated saliva was passively collected for determination of saliva insulin at baseline, and then weekly for 8 weeks. Saliva insulin was determined by Enzyme-linked immunosorbent assay (ELISA) using a commercially available kit and microplate spectrophotometer.

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026